Managed Care Cast Presents: Navigating Burdens and Treatment Challenges of IPF

The Orphan Drug Act in the Modern Drug Pricing Era

Finance Committee leaders propose expanding Medicare negotiation, curbing middlemen, and reinvesting in biomedical innovation as part of a 2026 health care affordability strategy.

ACOs Improve Primary, Preventive Care Delivery for Medicare Beneficiaries

Policy strategist Kristi Martin discusses how the Orphan Drug Act reshapes rare disease treatment and drug-pricing challenges.

Listen

Patient-centered care. | Image Credit_ Fabio Balbi - stock.adobe.com

Reflecting on 15 Years of Health IT Evolution and What’s Next: Nate C. Apathy, PhD

Beneficiaries in ACOs receive significantly higher rates of primary and preventive services, signaling value-based care’s impact on quality and chronic disease management.

January 27th 2026

Telomere Length and Polygenic Risk Shape Endotypes in Idiopathic Pulmonary Fibrosis

Nate C. Apathy, PhD, guest editor of AJMC's 15th Health IT special issue, calls for tools to be closely aligned with user needs.

Listen

A Lancet Respiratory Medicine study links telomere shortening and polygenic risk to distinct genetic endotypes in IPF. | Image Credit: lucadp-Adobestockjpeg

Is Rare Disease Policy a Stress Test of US Health Care?

Telomere length and polygenic risk independently influence IPF susceptibility, even among patients without rare genetic variants.

Rarediseaseawareness | Image Credit: © Penwin-stock.adobe.com

Senate Democrats Outline Drug Pricing Agenda to Cut Patient Costs

The Orphan Drug Act revolutionized rare disease treatment, yet rising costs and access issues challenge equitable health care solutions.

Related Content

The Orphan Drug Act in the Modern Drug Pricing Era

Finance Committee leaders propose expanding Medicare negotiation, curbing middlemen, and reinvesting in biomedical innovation as part of a 2026 health care affordability strategy.

ACOs Improve Primary, Preventive Care Delivery for Medicare Beneficiaries

Policy strategist Kristi Martin discusses how the Orphan Drug Act reshapes rare disease treatment and drug-pricing challenges.

Listen

Reflecting on 15 Years of Health IT Evolution and What’s Next: Nate C. Apathy, PhD

Beneficiaries in ACOs receive significantly higher rates of primary and preventive services, signaling value-based care’s impact on quality and chronic disease management.

January 27th 2026

Telomere Length and Polygenic Risk Shape Endotypes in Idiopathic Pulmonary Fibrosis

Nate C. Apathy, PhD, guest editor of AJMC's 15th Health IT special issue, calls for tools to be closely aligned with user needs.

Listen

Is Rare Disease Policy a Stress Test of US Health Care?

Telomere length and polygenic risk independently influence IPF susceptibility, even among patients without rare genetic variants.